CYDY News and Press, CytoDyn Inc From 03/29/21

CytoDyn (CYDY) announces that the Republic of the Philippines, Department of Health, Food and Drug Administration has approved the use of leronlimab to treat a COVID-19 patient under Compassionate Special Permit ((CSP)) pursuant to FDA Order No. 2016-005. The Company is shipping leronlimab to...

CD12 trial results also indicated that five out of six patients on ECMO recovered VANCOUVER, Washington, March 29, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , ("CytoDyn" or the "Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-P...

CytoDyn is simultaneously pursuing EUA in the Philippines while expanding its access under CSP VANCOUVER, Washington, March 29, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , ("CytoDyn" or the "Company"), a late-stage biotechnology company developing Vyrologix™ (l...

NEW YORK, March 19, 2021 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against CytoDyn, Inc. (“CytoDyn” or the “Company”) (OTCQB: CYDY) in the United States District Court for the Western District of Washin...

VANCOUVER, Washington, March 17, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic ...

Trial data is supportive of an EUA: Leronlimab outperformed every approved or recommended drug in critically ill patients. Shorts have a flawed analysis that doesn’t correct for patient age distribution. The clinical outcome of length of hospitalization was statistical...

CytoDyn (CYDY) promotes Christopher Recknor to the role of Chief Operating Officer.In his role as COO, Dr. Recknor will assist the senior management team to define and implement the overall business strategy and clinical development priorities, along with the requisite timelines. Dr. Rec...

Dr. Recknor will continue to oversee the Company's COVID-19 long-haulers and Phase 2 NASH trials VANCOUVER, Washington, March 16, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , ("CytoDyn" or the "Company"), a late-stage biotechnology company developing Vyrologix™...

CytoDyn's drug leronlimab (PRO-140) is not a failure. Bears are dismissing the efficacy of the drug by focusing solely on the shortcomings of management. Leronlimab has multiple indications with an excellent safety record and is worth more than the $1.5 billion market cap of the c...

CytoDyn recently reported Leronlimab's CD12 severe-to-critical data. The numbers were lackluster and failed to hit endpoints. Consequently, the bears have remerged and have triggered a substantial sell-off. After some analysis, the company revealed a subset of patients who benefited f...